Showing results (1-10 of 10) with videos related to
Sort By:
Pageof 1
Clinical Physiology and Functional Imaging|December 20, 2014
Myocardial uptake of bone scintigraphic agents associated with increased pulmonary uptakeTore Bach-Gansmo, Tale N Wien, Ayca Løndalen, et al.Acta Oncologica (Stockholm, Sweden)|August 24, 2021
Myelosuppression in patients treated with <sup>177</sup>Lutetium-lilotomab satetraxetan can be predicted with absorbed dose to the red marrow as the only variableJohan Blakkisrud, Ayca Løndalen, Jostein Dahle, et al.Molecular Imaging and Biology|April 29, 2022
FDG PET/CT and Dosimetric Studies of <sup>177</sup>Lu-Lilotomab Satetraxetan in a First-in-Human Trial for Relapsed Indolent non-Hodgkin Lymphoma-Are We Hitting the Target?Ayca Løndalen, Johan Blakkisrud, Mona-Elisabeth Revheim, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 3, 2016
Red Marrow-Absorbed Dose for Non-Hodgkin Lymphoma Patients Treated with 177Lu-Lilotomab Satetraxetan, a Novel Anti-CD37 Antibody-Radionuclide ConjugateJohan Blakkisrud, Ayca Løndalen, Jostein Dahle, et al.European Journal of Nuclear Medicine and Molecular Imaging|February 23, 2018
Pre-dosing with lilotomab prior to therapy with <sup>177</sup>Lu-lilotomab satetraxetan significantly increases the ratio of tumor to red marrow absorbed dose in non-Hodgkin lymphoma patientsCaroline Stokke, Johan Blakkisrud, Ayca Løndalen, et al.European Journal of Nuclear Medicine and Molecular Imaging|November 16, 2020
FDG PET/CT parameters and correlations with tumor-absorbed doses in a phase 1 trial of <sup>177</sup>Lu-lilotomab satetraxetan for treatment of relapsed non-Hodgkin lymphomaAyca Løndalen, Johan Blakkisrud, Mona-Elisabeth Revheim, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 30, 2017
Biodistribution and Dosimetry Results from a Phase 1 Trial of Therapy with the Antibody-Radionuclide Conjugate <sup>177</sup>Lu-Lilotomab SatetraxetanJohan Blakkisrud, Jon Erik Holtedahl, Ayca Løndalen, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 6, 2016
Tumor-Absorbed Dose for Non-Hodgkin Lymphoma Patients Treated with the Anti-CD37 Antibody Radionuclide Conjugate 177Lu-Lilotomab SatetraxetanJohan Blakkisrud, Ayca Løndalen, Anne C T Martinsen, et al.Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|September 16, 2022
Risk of recurrence after chemoradiotherapy identified by multimodal MRI and 18F-FDG-PET/CT in locally advanced cervical cancerKjersti Skipar, Tord Hompland, Kjersti Vassmo Lund, et al.Blood Advances|September 3, 2020
Phase 1/2a study of 177Lu-lilotomab satetraxetan in relapsed/refractory indolent non-Hodgkin lymphomaArne Kolstad, Tim Illidge, Nils Bolstad, et al.Pageof 1